Gyre Therapeutics/$GYRE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Gyre Therapeutics

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Ticker

$GYRE
Sector
Primary listing

Employees

579

GYRE Metrics

BasicAdvanced
$667M
432.35
$0.02
-
-

Bulls say / Bears say

Gyre’s lead candidate Hydronidone achieved statistically significant fibrosis regression versus placebo (52.85% vs. 29.84%, P=0.0002) in a pivotal Phase 3 CHB-associated liver fibrosis trial, with a favorable safety profile supporting an NDA submission in Q3 2025 for potential first-in-class approval (GlobeNewswire) (Nasdaq)
In Q2 2025, revenues increased 6.3% year-on-year to $26.8 million, driven primarily by Etorel’s launch contributing $1.6 million and Contiva’s $1.5 million in sales, demonstrating successful diversification beyond ETUARY (Gyre Therapeutics IR) (TipRanks)
The May 2025 public offering and exercise of underwriters’ option generated gross proceeds of ~$23 million, boosting Gyre’s cash and equivalents to $75.9 million as of June 30, 2025, providing a runway to fund Phase 2 trials and operations for at least 12 months (Gyre Therapeutics IR) (SEC Filing)
ETUARY sales declined by $5.2 million in Q1 2025 compared to Q1 2024, contributing to an 18.7% year-on-year revenue drop and highlighting challenges in sustaining its core franchise amid shifting marketing strategies and competitive pressures (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GYRE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs